SCHEMBL4513802

SCHEMBL4513802

COc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2)c2c1C[C@@H](N1CCCC1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.53
QRFPR Q96P65 1/20 0.53
HSD11B1 P28845 1/20 0.45
HSD17B2 P37059 1/20 0.45
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HTT P42858 1/20 0.43
TRIM24 O15164 1/20 0.43
ALDH1A1 P00352 3/20 0.43
PI4KB Q9UBF8 1/20 0.43
TP53 P04637 2/20 0.43
KMT2A Q03164 1/20 0.43
HTR1A P08908 3/20 0.42
DRD2 P14416 3/20 0.42
HTR1D P28221 3/20 0.42
HTR1B P28222 3/20 0.42
HTR2A P28223 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520356 0.91 HTR6 (0.52) HTR6QRFPRHSD11B1HSD17B2NPSR1
SCHEMBL4524885 0.90 HSD11B1 (0.52) HTR6QRFPRHSD11B1HSD17B2LMNA
SCHEMBL4519556 0.89 HTR6 (0.48) HTR6QRFPRHSD11B1HSD17B2LMNA
SCHEMBL4527076 0.89 THRB (0.56) HTR6QRFPRHSD11B1HSD17B2NPSR1
SCHEMBL4518573 0.88 HTR6 (0.69) HTR6QRFPRLMNAPOLBMAPT
SCHEMBL4522637 0.87 HSD11B1 (0.48) HTR6QRFPRHSD11B1HSD17B2LMNA
SCHEMBL4960787 0.87 HSD11B1 (0.48) HTR6QRFPRHSD11B1HSD17B2LMNA
SCHEMBL4962886 0.83 HTR6 (0.57) HTR6QRFPRHSD11B1HSD17B2NPSR1
SCHEMBL4512908 0.83 HTR6 (0.57) HTR6QRFPRHSD11B1HSD17B2NPSR1
SCHEMBL4522172 0.83 GAA (0.56) HTR6QRFPRHSD11B1HSD17B2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US claimed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
EP-1888518-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126938-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor HTR6, HTR1D, HTR1A HTR6 1/4885QRFPR 79/4885HSD11B1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.